Steven D. Nathan
Rank 57 by 10-year citations to CLAD papers (27 papers, 458 citations). "Medical Director" (Department of Medicine, Inova Fairfax Hospital); field: respiratory medicine.
As of . Primary source: ORCID record (role and affiliation entries are self-asserted).
Summary
Steven D. Nathan. Role: ORCID lists "Medical Director" (Department of Medicine, Inova Fairfax Hospital). Basis of the role: ORCID employment entries without an end date (self-asserted by the record holder, may be out of date). Field indicated by the unit name: respiratory medicine (source: affiliation lines on the author's own papers, for example https://doi.org/10.3390/jcm15197623 (2026): "Advanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Health System, 3300 Gallows Rd, Falls Church, VA 22042, USA"; also on https://doi.org/10.1016/j.rmed.2026.109138, https://doi.org/10.1016/j.jhlto.2026). Affiliation: Inova Fairfax Hospital, Falls Church (US). Basis: ORCID record, employment entries without an end date (self-asserted, may be out of date). Counts in the OpenAlex corpus (retrieved 2026-10-10): 27 papers and 458 citations over ten years; 0 first-author and 3 last-author papers. Ranks: main 57, excluding consensus papers 46, first or last author 407. The method is stated once on the People list page. Linked papers are the most-cited corpus papers of this author.
Citation ranks (10 years)
| Main rank | Rank excluding consensus papers | Rank by first or last author papers |
|---|---|---|
| 57 of 800 | 46 of 794 | 407 of 512 |
Citations: 458 in total, 458 excluding consensus and guideline papers (0 of this author's papers excluded), 2 on first or last author papers (0 first, 3 last).
Ranking method: see the methodology note at the top of the People list and the full methodology document.
Role and field
- Role
- "Medical Director" (Department of Medicine, Inova Fairfax Hospital)
- Role status
- verified from ORCID (self-asserted entries; may be out of date)
- Role basis
- ORCID employment entries without an end date (self-asserted by the record holder, may be out of date)
- Field
- respiratory medicine
- Field basis
- affiliation lines on the author's own papers, for example https://doi.org/10.3390/jcm15197623 (2026): "Advanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Health System, 3300 Gallows Rd, Falls Church, VA 22042, USA"; also on https://doi.org/10.1016/j.rmed.2026.109138, https://doi.org/10.1016/j.jhlto.2026
Only what a cited source supports is stated. Entries marked self-asserted come from the person's own ORCID record. The field is taken from the name of the unit, not inferred from the person's name.
Details
- affiliation
- Inova Fairfax Hospital, Falls Church (US)
- papers 10y
- 27
- fractional papers 10y
- 2.06
- citations 10y
- 458
- fractional citations 10y
- 24.8
- ranking retrieved
- 2026-10-10
- orcid
- 0000-0002-6270-1617
- openalex author id
- A5052485494
- merged open alex profiles
- 3
- affiliation basis
- ORCID record, employment entries without an end date (self-asserted, may be out of date)
- papers excluding consensus 10y
- 27
- citations excluding consensus 10y
- 458
- consensus papers excluded 10y
- 0
- first author papers 10y
- 0
- last author papers 10y
- 3
- lead author citations 10y
- 2
- lead author papers 10y
- 3
Sources and links
- ORCID record (role and affiliation entries are self-asserted) (primary)
- OpenAlex author profile (ranking source)
- Most-cited CLAD paper in corpus: Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD) (The Journal of Heart and Lung Transplantation, 2021); 55 citations; DOI 10.1016/j.healun.2021.02.008
- Most-cited CLAD paper in corpus: Preemptive treatment of de novo donor-specific antibodies in lung transplant patients reduces subsequent risk of chronic lung allograft dysfunction or death (American Journal of Transplantation, 2023); 27 citations; DOI 10.1016/j.ajt.2022.12.019
- Most-cited CLAD paper in corpus: Extreme elevations of donor-derived cell-free DNA increases the risk of chronic lung allograft dysfunction and death, even without clinical manifestations of disease (The Journal of Heart and Lung Transplantation, 2024); 16 citations; DOI 10.1016/j.healun.2024.04.064
- Most-cited CLAD paper in corpus: Donor–derived cell-free DNA associated with increased risk of chronic lung allograft dysfunction and mortality: Are absolute levels better than percentage? (The Journal of Heart and Lung Transplantation, 2026); 9 citations; DOI 10.1016/j.healun.2026.01.022
- Most-cited CLAD paper in corpus: Restrictive Allograft Syndrome Patients Have Higher Cell-Free DNA Assessed Allograft Injury Prior to Diagnosis (The Journal of Heart and Lung Transplantation, 2022); 3 citations; DOI 10.1016/j.healun.2022.01.043
- ORCID employment entries (source of the role)
- Own paper naming the unit (affiliation line)
- Own paper naming the unit (affiliation line)
Known gaps in this record
- centre membership relation (not asserted)
- funding and conflicts of interest
- only the top-30 entries were checked by hand for ID merges and splits
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.